Benzinga · Nov 10, 2026
Pacific Biosciences Of California Enters Into Sales Agreement With Allen & Co. To Sell Common Stock With Aggregate Proceeds Of Up To $100M, Through At-The-Market Equity Offering Program
-SEC Filing
PA
NASDAQ · PACB
Pacific Biosciences of California, Inc.
Healthcare · Medical - Devices
$1.96
Down-$0.01 (-0.51%)
Updated Nov 15, 2026, 10:43 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 652.12M
- P/E ratio
- -1.29
- Dividend yield
- 0.00%
- 52-week range
- $1.07 – $3.44
- Volume
- 7.02M
- Avg. volume
- 9M
Price performance · PACB
PACB price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 13, 2026
PACB closed at $1.96 after 20 trading sessions, up 6.52% for the selected period.
- Last close
- $1.96
- Period change
- +6.52%
- Period low
- $1.84
- Period high
- $2.90
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | $1.99 | $2.00 | $1.84 | $1.96 | 7.02M |
| Nov 12, 2026 | $1.99 | $2.06 | $1.80 | $1.97 | 10.34M |
| Nov 11, 2026 | $2.29 | $2.3486 | $2.07 | $2.09 | 10.69M |
| Nov 10, 2026 | $2.31 | $2.345 | $2.12 | $2.24 | 8.89M |
| Nov 9, 2026 | $2.23 | $2.43 | $2.16 | $2.36 | 11.84M |
| Nov 6, 2026 | $2.43 | $2.54 | $2.24 | $2.255 | 9.56M |
| Nov 5, 2026 | $2.24 | $2.69 | $2.23 | $2.43 | 20.58M |
| Nov 4, 2026 | $2.53 | $2.70 | $2.48 | $2.55 | 20.97M |
| Nov 3, 2026 | $2.41 | $2.5799 | $2.4001 | $2.44 | 6.26M |
| Nov 2, 2026 | $2.68 | $2.7194 | $2.31 | $2.345 | 9.1M |
| Oct 30, 2026 | $2.75 | $2.82 | $2.4101 | $2.605 | 13.74M |
| Oct 29, 2026 | $2.775 | $2.96 | $2.74 | $2.90 | 11.97M |
| Oct 28, 2026 | $2.45 | $3.065 | $2.44 | $2.83 | 35.05M |
| Oct 27, 2026 | $2.26 | $2.525 | $2.23 | $2.45 | 18.69M |
| Oct 26, 2026 | $2.12 | $2.305 | $2.08 | $2.25 | 9.57M |
| Oct 23, 2026 | $2.02 | $2.13 | $1.97 | $2.11 | 5.72M |
| Oct 22, 2026 | $2.13 | $2.21 | $2.05 | $2.06 | 9.18M |
| Oct 21, 2026 | $1.965 | $2.1891 | $1.92 | $2.14 | 13.5M |
| Oct 20, 2026 | $1.815 | $2.06 | $1.7601 | $1.96 | 10.36M |
| Oct 19, 2026 | $1.78 | $1.86 | $1.74 | $1.84 | 6.04M |
Latest PACB news
The latest Smart Investors Daily articles mentioning PACB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PACB research
Overview
Company profile and research snapshot.
Company profile
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 9, 2026 | UBS | Neutral | — |
| Nov 5, 2026 | Piper Sandler | Neutral | — |
| Nov 5, 2026 | Barclays | Underweight | — |
| May 11, 2026 | Barclays | Underweight | — |
| Apr 14, 2026 | Barclays | Underweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Nov 9, 2026
Pacific Biosciences of California, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-09. The following slide deck was published by Pacific Biosciences of California, Inc.
Benzinga · Nov 9, 2026
UBS Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.7
UBS analyst Doug Schenkel maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $3.05 to $2.7.
SeekingAlpha · Nov 5, 2026
Pacific Biosciences Q3: Another Revenue Guidance Cut
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
